JIMD Reports - Case and Research Reports, 2012/1 pp 125-128 | Cite as
Report of a Large Brazilian Family With a Very Attenuated Form of Hunter Syndrome (MPS II)
- 8 Citations
- 514 Downloads
Abstract
Hunter syndrome, or Mucopolysaccharidosis type II (MPS II), is a rare X-linked recessive disorder caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS). The phenotypic spectrum varies from severe to attenuated clinical forms. We report a large Brazilian family with 16 affected individuals exhibiting a very attenuated form of MPS II. Fourteen female carriers were also identified. Twelve affected male patients, whose ages ranged from 1 to 35 years, were examined. Molecular analysis showed a novel missense mutation (p.A77D) in the IDS gene, confirming the diagnosis. Nine of the family members presented some degree of heart damage, though only the proband became symptomatic and required heart transplantation. One 19-year-old adult and 1-year-old twin boys each had a normal echocardiogram. Short stature was found in two adults while macrocephaly was found in one; the remaining adults had anthropometric measures within normal range. All affected adults had normal cognitive development and were able to perform normal daily activities, except one who had mild learning disability. Two patients died due to natural causes beyond 70 years of age. The female carriers did not present any signs of disease. In this large family with a mild form of MPS II and variable degree of clinical manifestations, it is noteworthy that several affected individuals have remained asymptomatic even at advanced age and even without enzyme replacement therapy.
Keywords
Hearing Loss Enzyme Replacement Therapy Umbilical Hernia Acute Decompensated Heart Failure Corneal OpacityReferences
- DiFerrante N, Nichols BL (1972) A case of the Hunter syndrome with progeny. Johns Hopkins Med J 130(5):325–328PubMedGoogle Scholar
- Martin R, Beck M, Eng C, Giugliani R, Harmatz P, Muñoz V, Muenzer J (2008) Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 121(2):e377–e386, ReviewPubMedCrossRefGoogle Scholar
- Muenzer J, Beck M, Eng CM, Escolar ML, Giugliani R, Guffon NH, Harmatz P, Kamin W, Kampmann C, Koseoglu ST, Link B, Martin RA, Molter DW, Muñoz Rojas MV, Ogilvie JW, Parini R, Ramaswami U, Scarpa M, Schwartz IV, Wood RE, Wraith E (2009) Multidisciplinary management of Hunter syndrome. Pediatrics 124(6):e1228–e1239, Epub 2009 Nov 9. ReviewPubMedCrossRefGoogle Scholar
- Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, Ramaswami U, Vellodi A, Wraith JE, Cleary M, Gucsavas-Calikoglu M, Puga AC, Shinawi M, Ulbrich B, Vijayaraghavan S, Wendt S, Conway AM, Rossi A, Whiteman DA, Kimura A (2011) Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med 13(2):95–101PubMedCrossRefGoogle Scholar
- Sasaki CT, Ruiz R, Gaito R Jr, Kirchner JA, Seshi B (1987) Hunter’s syndrome: a study in airway obstruction. Laryngoscope 97(3 Pt 1):280–285PubMedGoogle Scholar
- Scarpa M (2011) Mucopolysaccharidosis Type II. In: GeneReviews at GeneTests – Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997–2011. Available at http://www.genetests.org. Accessed 24 May 2011
- Wraith JE, Beck M, Giugliani R, Clarke J, Martin R, Muenzer J (2008a) HOS Investigators Initial report from the Hunter Outcome Survey. Genet Med 10:508–516PubMedCrossRefGoogle Scholar
- Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, Lund AM, Malm G, Van der Ploeg AT, Zeman J (2008b) Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167:267–277PubMedCrossRefGoogle Scholar